[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200003879T2 - İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ - Google Patents

İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@

Info

Publication number
TR200003879T2
TR200003879T2 TR2000/03879T TR200003879T TR200003879T2 TR 200003879 T2 TR200003879 T2 TR 200003879T2 TR 2000/03879 T TR2000/03879 T TR 2000/03879T TR 200003879 T TR200003879 T TR 200003879T TR 200003879 T2 TR200003879 T2 TR 200003879T2
Authority
TR
Turkey
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
radiation therapy
sensitizing properties
Prior art date
Application number
TR2000/03879T
Other languages
English (en)
Inventor
Franciscus Van Ginckel Robert
Joanna Floren Wim
William End David
Boudew�Jn Leopold Wouters Walter
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of TR200003879T2 publication Critical patent/TR200003879T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Bu buluş, farnesil protein transferaz inhibitörlerinin, ışın tedavisine duyarlılaştırıcı özelliklere sahip oldukları bulgusuna ilişkindir. bu özellikler, in vivo kanser tedavisi için bir tümörün ışın tedavisinden önce, ışın tedavisi sırasında veya sonrasında uygulanmak üzere farmasötik bir bileşimin hazırlanmasında faydalı olmalarını sağlar.
TR2000/03879T 1998-07-06 1999-06-30 İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ TR200003879T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP98204330 1998-12-18

Publications (1)

Publication Number Publication Date
TR200003879T2 true TR200003879T2 (tr) 2007-01-22

Family

ID=26150503

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03879T TR200003879T2 (tr) 1998-07-06 1999-06-30 İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@

Country Status (31)

Country Link
US (1) US6545020B1 (tr)
EP (1) EP1094839B1 (tr)
JP (1) JP4530537B2 (tr)
KR (1) KR100591603B1 (tr)
CN (1) CN1152716C (tr)
AP (1) AP1599A (tr)
AT (1) ATE238811T1 (tr)
AU (1) AU762423B2 (tr)
BG (1) BG64941B1 (tr)
BR (1) BR9911861A (tr)
CA (1) CA2336624C (tr)
CZ (1) CZ300968B6 (tr)
DE (1) DE69907461T2 (tr)
DK (1) DK1094839T3 (tr)
EA (1) EA003877B1 (tr)
EE (1) EE04582B1 (tr)
ES (1) ES2199579T3 (tr)
HK (1) HK1034451A1 (tr)
HR (1) HRP20000903A2 (tr)
HU (1) HU229076B1 (tr)
ID (1) ID26987A (tr)
IL (2) IL140721A0 (tr)
MY (1) MY126519A (tr)
NO (1) NO328178B1 (tr)
PL (1) PL193464B1 (tr)
PT (1) PT1094839E (tr)
SI (1) SI1094839T1 (tr)
SK (1) SK284723B6 (tr)
TR (1) TR200003879T2 (tr)
TW (1) TW586937B (tr)
WO (1) WO2000001411A1 (tr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337800C (en) 1998-07-06 2007-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
IL140721A0 (en) 1998-07-06 2002-02-10 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
ES2262626T3 (es) * 2000-02-04 2006-12-01 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para tratar cancer de mama.
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
JP4911866B2 (ja) 2000-09-25 2012-04-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼ阻害剤としてのファルネシルトランスフェラーゼを阻害するキノリンおよびキナゾリン誘導体
JP4974437B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
DE60135919D1 (de) 2000-09-25 2008-11-06 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1351954B1 (en) * 2000-12-27 2006-05-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
DE60231646D1 (de) 2001-12-19 2009-04-30 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
ATE364384T1 (de) 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
JP4384505B2 (ja) 2002-04-15 2009-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US7855207B2 (en) * 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP2009508809A (ja) 2005-07-29 2009-03-05 チルドレンズ ホスピタル メディカル センター ＲＡＣ−１ＧＴＰａｓｅのＧＴＰａｓｅ阻害因子とその使用方法およびその結晶構造
JP2009521470A (ja) 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
CA2687976C (en) * 2007-05-23 2015-04-07 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
ATE555384T1 (de) 2008-06-26 2012-05-15 Spherotec Gmbh Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
CN105209453B (zh) 2012-10-16 2017-06-20 詹森药业有限公司 ROR‑γ‑T的亚甲基连接的喹啉基调节剂
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
ES2770727T3 (es) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
CN105848483A (zh) 2013-10-15 2016-08-10 詹森药业有限公司 RORγt 的喹啉基调节剂
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
TWI710642B (zh) 2015-08-17 2020-11-21 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
HUE053927T2 (hu) 2016-11-03 2021-07-28 Kura Oncology Inc Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3432883B1 (en) 2017-02-21 2021-07-28 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3071854A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3117968A1 (en) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3134825A1 (en) 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (ru) 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania SENSITIZATION OF CELLS FOR RADIATION AND CHEMOTHERAPY
JP2000514456A (ja) * 1996-07-15 2000-10-31 ブリストル―マイヤーズ・スクイブ・カンパニー ファルネシルプロテイントランスフェラーゼのチアジオキソベンゾジアゼピン阻害剤
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
IL140721A0 (en) 1998-07-06 2002-02-10 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
JP4090200B2 (ja) * 1999-02-11 2008-05-28 ファイザー・プロダクツ・インク 抗癌薬として有用なヘテロアリール置換キノリン−２−オン誘導体

Also Published As

Publication number Publication date
ID26987A (id) 2001-02-22
KR100591603B1 (ko) 2006-06-20
TW586937B (en) 2004-05-11
BG64941B1 (bg) 2006-10-31
ES2199579T3 (es) 2004-02-16
SI1094839T1 (en) 2003-12-31
EE04582B1 (et) 2006-02-15
DE69907461D1 (de) 2003-06-05
CA2336624A1 (en) 2000-01-13
AU762423B2 (en) 2003-06-26
BG105108A (en) 2001-11-30
EP1094839A1 (en) 2001-05-02
PL193464B1 (pl) 2007-02-28
CN1311692A (zh) 2001-09-05
EP1094839B1 (en) 2003-05-02
HUP0103689A2 (hu) 2002-02-28
CZ300968B6 (cs) 2009-09-30
KR20010052770A (ko) 2001-06-25
ATE238811T1 (de) 2003-05-15
CA2336624C (en) 2008-10-21
US6545020B1 (en) 2003-04-08
AU4780599A (en) 2000-01-24
EE200000794A (et) 2002-06-17
NO20010082L (no) 2001-01-05
NO20010082D0 (no) 2001-01-05
AP1599A (en) 2006-04-27
WO2000001411A1 (en) 2000-01-13
IL140721A (en) 2008-11-26
DE69907461T2 (de) 2004-02-19
JP4530537B2 (ja) 2010-08-25
IL140721A0 (en) 2002-02-10
CZ20004777A3 (en) 2001-05-16
SK19862000A3 (sk) 2001-12-03
HRP20000903A2 (en) 2001-12-31
PT1094839E (pt) 2003-09-30
HU229076B1 (en) 2013-07-29
PL347979A1 (en) 2002-05-06
EA200100111A1 (ru) 2001-06-25
SK284723B6 (sk) 2005-10-06
MY126519A (en) 2006-10-31
JP2002519389A (ja) 2002-07-02
DK1094839T3 (da) 2003-08-18
HK1034451A1 (en) 2001-10-26
AP2001002057A0 (en) 2001-03-31
EA003877B1 (ru) 2003-10-30
HUP0103689A3 (en) 2003-01-28
NO328178B1 (no) 2009-12-28
CN1152716C (zh) 2004-06-09
BR9911861A (pt) 2001-03-20

Similar Documents

Publication Publication Date Title
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
BR112023022819A2 (pt) Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
CY1106601T1 (el) Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου
CY1106259T1 (el) Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
DK0616812T3 (da) Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
CY1105803T1 (el) Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου
ATE260666T1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
ZA201907225B (en) Treatment of her2 positive cancers
CY1125126T1 (el) Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
DE60038624D1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
CY1106525T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer